News

CCDC Scientist Awarded Prestigious BACG Young Scientists Award


Dr Pietro Sacchi Wins the Award for Ground-Breaking Work Providing Practical Solutions to Long-Standing Challenges in Drug Development and Manufacturing


Cambridge, UK – 12 July 2024 – We are pleased to announce that Dr Pietro Sacchi, Research and Application Scientist at the CCDC, has been awarded the British Association for Crystal Growth (BACG) Young Scientists Award for his exceptional research on the HIV drug ritonavir.

The pharmaceutical landscape is evolving rapidly, and staying ahead requires a deep understanding of the current trends and challenges. This comprehensive report provides a critical analysis of the drug development industry, focusing on the health of pipelines, the strategic focus of biotechs and pharmacos, and the capacity of regulators like the FDA to manage the influx of novel therapies.


DOWNLOAD NOW


 
AMSBIO offers a wide range of products to support skeletal muscle cell culture enabling you to streamline your modelling process in vitro.

With the new Labour government pledging to 'build an NHS fit for the future', an injection of money, whilst welcome, will not be enough - it must be rolled out in a measured and integrated way that works more closely with the private sector in order to make a real difference, says RSM UK. 

Read July's eNews here


Featuring:

Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the closing of its series A financing raising £90m ($114m). The round was co-led by new leading life science investors Novo Holdings and Abingworth.

 
The NHS’ Health Research Authority (HRA) recently published its draft template Investigator Initiated Study Agreement (IIS Agreement)and called for comments on the draft.   


According to the HRA, and in a similar way to the other model agreements used for other types of clinical trials conducted in the UK, the IIS Agreement is intended to act as a “standard contract agreement template” for use between non-commercial sponsors and commercial organisations providing support for investigator-initiated studies. 

Pages